A Double-Blind, Placebo-Controlled Study Examining The Safety, Efficacy, and Tolerability of SEP-225289 in Subjects With Major Depressive Disorder (Including Atypical and Melancholic Features).

Trial Profile

A Double-Blind, Placebo-Controlled Study Examining The Safety, Efficacy, and Tolerability of SEP-225289 in Subjects With Major Depressive Disorder (Including Atypical and Melancholic Features).

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2010

At a glance

  • Drugs Dasotraline (Primary) ; Venlafaxine
  • Indications Depression; Major depressive disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 23 Dec 2009 Actual patient number changed from 514 to 523 as reported by ClinicalTrials.gov.
    • 02 Jul 2009 Primary endpoint 'Hamilton Depression Rating Scale' has not been met.
    • 27 Jun 2009 Status changed from active, no longer recruiting to completed, according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top